Skip to main content

Van Baerle to benefit from Schweizerhalle location

| News

Van Baerle to benefit from Schweizerhalle location

13.11.2018

Next year, chemical company Van Baerle will move from Münchenstein in the canton of Basellandschaft to the Schweizerhalle industrial location. Owner and CEO Daniel Schenk summarized the advantages of the new location in an interview.

Lager Hygieneprodukte, Standort Münchenstein (img. van Baerle)

Van Baerle is leaving Münchenstein after some 130 years because the site is too large for the company, explained Daniel Schenk in an interview. “We have over 20,000 square metres here, while at the new location it will still be around 10,000 square metres.”

But that is not the only reason for staying in the Basel region. Van Baerle is relocating to the chemical and pharmaceutical cluster in Schweizerhalle in the immediate vicinity of companies such as Novartis. Although this proximity was not the decisive factor in favour of the new location, Van Baerle is still set to benefit from it. “We need alkalis for our production – and these are produced in Schweizerhalle,” said Schenk. “We will also be able to exploit synergies in supply with water and steam as well as wastewater.”

The Basel economic development agency proposed the new location to Van Baerle.

For Van Baerle, relocating abroad would not have generated enough advantages. Schenk cited the “solid economic reasons that speak in favour of Switzerland as a business location”. He said that the legal framework in Switzerland enables flexibility and entrepreneurial action and named training and the labour market as other arguments in favour of Switzerland.

Schenk also said that he cannot imagine a Switzerland without industrial activities: “This might be possible for very small countries such as Monaco or Liechtenstein, but not for Switzerland. We have to take care of our workplace.” He added that Swissness will still play a role internationally, even if production costs are lower abroad.

Particularly in the Basel region, the planned reduction in the corporate tax rate is also attractive for the company, even if the privileges of a holding company no longer exist. “The bottom line is that Van Baerle will benefit”, concluded Schenk.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.